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ABSTRACT
Powell, Katherine M. M.S.B.M.E., Purdue University, May 2019. The Effects of
Zoledronate and Raloxifene Combination Therapy on Diseased Mouse Bone. Major
Professor: Joseph M. Wallace.
Current interventions used to reduce skeletal fragility are insufficient at enhancing
bone across multiple hierarchical levels. Bisphosphonates, such as Zoledronate (ZOL),
treat a variety of bone disorders by increasing bone mass and bone mineral density
to decrease fracture risk. Despite the mass-based improvements, bisphosphonate use
has been shown to compromise bone quality. Alternatively, Raloxifene (RAL) has re-
cently been demonstrated to improve tissue quality and overall mechanical properties
by binding to collagen and increasing tissue hydration in a cell-independent manner.
We hypothesized that a combination of RAL and ZOL would improve mechanical
and material properties of bone more than either monotherapy alone by enhancing
both quantity and quality of bone. In this study, wildtype (WT) and heterozy-
gous (OIM+/-) male mice from the Osteogenesis Imperfecta (OI) murine model were
treated with either RAL, ZOL, or RAL and ZOL from 8 weeks to 16 weeks of age.
Combination treatment resulted in higher trabecular architecture, cortical mechani-
cal properties, and cortical fracture toughness in diseased mouse bone. Two fracture
toughness properties, direct measures of the tissues ability to resist the initiation and
propagation of a crack, were significantly improved with combination treatment in
OIM+/- compared to control. There was no significant effect on fracture toughness
with either monotherapy alone in either genotype. Following the mass-based effects
of ZOL, bone volume fraction was significantly higher with combination treatment in
both genotypes. Similar results were seen in trabecular number. Combination treat-
ment resulted in higher ultimate stress in both genotypes, with RAL additionally in-
xcreasing ultimate stress in OIM+/-. RAL and combination treatment in OIM+/- also
produced a higher resilience compared to the control. Given no significant changes
in cortical geometry, these mechanical alterations were likely driven by the quality-
based effects of RAL. In conclusion, this study demonstrates the beneficial effects
of using combination therapy to increase bone mass while simultaneously improving
tissue quality, especially to enhance the mechanical integrity of diseased bone. Com-
bination therapies could be a future mechanism to improve bone health and combat
skeletal fragility on multiple hierarchal levels.
1CHAPTER 1. INTRODUCTION
1.1 Bone Overview
Bone is organized in a hierarchal multiscale fashion with each level contributing to
its mechanical integrity. At the nanostuctural level, bone is a composite matrix con-
sisting of mineral, collagen, and noncollagenous proteins. The composite surrounds
and supports three types of bone cells: osteoblasts, osteoclasts, and osteocytes. These
cells produce and maintain the structure of the bone. The cells come together to form
lamellae, which layer upon each other to create macroscopic cortical and trabecular
bone. [1]
While it is often thought that bone mass and size affect the majority of the bones
mechanical behavior, the intrinsic quality of bone tissue can dramatically influence
the mechanical integrity of the bone. Tissue quality refers to the bones chemical and
physical properties without regard to its mass or macroscopic structure. This includes
the bones inherent ability to resist load. Some measurable parameters of bone quality
include tissue mineral density, chemical composition, degree of enzymatic collagen
cross-linking, microdamage, and accumulation of advanced glycation end-products
(AGEs). These parameters affect the microscopic composite and can alter the bones
ability to absorb energy and resist fracture. [2–6]
Numerous bone diseases and disorders cause skeletal fragility and increased frac-
ture risk. The American public faces 1.5 million fractures each year resulting in an
expense of over $18 billion just for direct care. [7] Current diagnosis tools and treat-
ment for skeletal fragility focus on improving bone mass and bone mineral density
(BMD). Unfortunately, the effect of bone tissue quality at the microscopic level is
2overlooked and is not targeted for therapy. Increasing bone mass, while simultane-
ously improving the quality of collagen-mineral tissue composite, has the potential
to become a unique strategy that improves fracture resistance and optimally reduces
skeletal fragility.
1.2 Poor Bone Quality
Numerous diseased states can cause bone quality to be compromised. Tissue at
the microscopic level can be altered, leading to increased fracture risk and poor bone
health. For example, diabetes can produce negative consequences and cause increased
fractures compared to normal healthy bone. In diabetic patients, it has been shown
that their increase blood glucose levels can cause an accumulations of AGEs in the
collagen mineral matrix. Though these patients normally have an average BMD,
diabetics have increased fracture risk due to their poor bone quality. [8]
Alterations in tissue quality can also be genetic. Osteogenesis imperfecta (OI) is
a genetic disease in bone caused by a mutation in Type I collagen or related proteins.
Over 1500 independent genome alterations have been identified that lead to mutated
OI collagen. This wide variety of mutations leads to varying clinically severity of
the disease. Patients with a mild form of OI may only experience a few fractures
throughout their lifetime, but those with a severe form may experience innumerable
breaks, often resulting from low energy impact. [9, 10]
OI is deemed brittle bone disease due to its dominant phenotype of increased
fracture risk. This risk of fractures roots from the poor quality bone tissue of OI.
The mutated collagen leads to poor formation of the triple helical structure, driv-
ing quality-based deficiencies in the collagen-mineral composite. [11–13] These mi-
croscopic changes induce macroscopic effects and cause brittle bones and frequent
fractures in patients suffering from the disease.
Current treatments used to combat OI and other modes of skeletal fragility do not
target the quality of the bone. Investigating therapeutics that beneficially alter the
3collagen mineral composite, rather than just increasing bone mass, offers a unique
strategy to combat fragility and increase the bones ability to resist fracture.
1.3 Bone Remodeling
Remodeling is the process of bone formation and resorption that the skeleton
undergoes to keep bones at optimal health. Remodeling removes areas of old or
damaged tissue, non-viable cells, or tissue with suboptimal properties, and replaces
these regions with new cells and tissue. Osteoclasts resorb and degrade bone, while
osteoblasts are the cells that form new bone. [14,15]
Osteocytes differentiate from osteoblasts that became trapped in the bone matrix
during formation. Osteocytes encompass over 90% of the cells in the matrix and
reside as chemical and mechanical sensor cells. Increasing evidence suggests that
osteocytes help regulate osteoblast and osteoclasts through mechanical and hormonal
cues. For example, osteocytes can detect microdamage in the matrix and signal to
the osteoclasts that the region needs to be remodeled. [16]
Diseases and disorders can occur when the remodeling process is disrupted. For
example, age-related osteoporosis presents due to a remodeling imbalance and causes
bone loss and fragility. In this case, age-related estrogen deficits lead to the prolonged
lifespan of osteoclasts, which results in more bone resorption that is not balanced by
formative refilling. [17] Over time, this results in loss of bone tissue and ultimately
bone fragility.
1.4 Bisphosphonates
Bisphosphonates (BPs) have been the gold standard treatment for numerous bone
disorders for the past 30 years. BPs target osteoclasts and decrease their activity,
which ultimately leads to the disruption of the bone remodeling process. BPs have
a high affinity for bone mineral. When osteoclasts attach to the surface and try to
resorb bone, the BPs act against them and decrease their activity.
4The type of class determines the mechanism upon which BPs act. Non-nitrogen-
containing BPs are taken up by osteoclasts upon resorption and disrupt their cellular
function, ultimately inducing apoptosis and overall decrease of osteoclasts. Nitrogen-
containing BPs stabilize the bone matrix and prevents it from being resorbed, reduc-
ing the efficacy of the osteoclasts. Zoledronate (ZOL) is an example of a nitrogen-
containing BP and is considered one of the most potent BPs. [18]
BPs increase bone mineral density which leads to decreased fracture risk in dis-
eases such as postmenopausal osteoporosis, Pagets disease, metastatic osteolytic le-
sions, and more recently, Osteogenesis Imperfecta. [19–21] Bisphosphonates target
osteoclasts and decrease their activity, which ultimately leads to the disruption of the
bone remodeling process. [22] Despite the increase in bone mass that occurs with the
use of BPs, long term use may have unintended consequences.
Tissue quality at the microscopic level is compromised with bisphosphonate use.
The disruption of bone remodeling shuts down the bone repair mechanism which can
lead to the accrual of microdamage in the tissue, making the tissue more susceptible
to failure. [23] There is also an increase in non-enzymatic cross linking in the colla-
gen matrix that has been correlated with reduced post-yield mechanical properties
and reduced bone toughness. [24–26] Although bisphosphonates have positive mass-
based effects in bone, tissue quality may not be optimal, making these treatments
insufficient to overcome mechanical deficits common with disease. There is a need to
simultaneously improve tissue quality while increasing mass.
1.5 Raloxifene
Raloxifene (RAL) is in a different class of FDA-approved drugs used to treat
osteoporosis in post-menopausal women. The drug primarily acts in a cell-dependent
manner as a Selective Estrogen Receptor Modulator (SERM) and combats bone loss
by binding and signaling through estrogen receptors on osteoblasts. [27] Clinically,
RAL reduces fractures by 50% but with modest changes in remodeling and BMD.
5[28–30] This observation suggests that the changes in mechanical integrity are driven
by tissue quality changes versus altered mass or architecture.
Recent work has demonstrated that RAL also exhibits cell-independent behavior
by binding to collagen and increasing tissue hydration, leading to enhanced mechani-
cal properties and fracture resistance. [31,32] These cell-independent, material-based
changes provide a unique opportunity to beneficially alter bone fracture resistance
through changes in tissue quality, especially in disease states that are driven by infe-
rior tissue properties.
1.6 Gap and Plan of Attack
Current treatments used to treat bone fragility are insufficient at improving bone
across multiple hierarchical levels. The purpose of this study was to use a com-
bination treatment to target different levels of bone to enhance overall mechanical
integrity. It was hypothesized that using the mass-based effects of BPs, in conjunc-
tion with the tissue level improvements noted with RAL, the combinatorial treatment
would improve bone mechanical properties and fracture resistance more than either
monotherapy alone.
The Osteogenesis Imperfecta murine (oim) model of OI was used for this study.
The oim model allows for investigation of how combination treatments impact the
phenotype of a quality-based disease state [33], where adding more, poor quality,
tissue with BPs might not be enough to overcome mechanical deficiencies.
6CHAPTER 2. MATERIALS AND METHODS
2.1 Animals and Treatment
All protocols and procedures were performed with prior approval from the IU
School of Medicine IACUC. Male wild-type (WT) and heterozygous (OIM +/-) mice
were bred from heterozygous parental strains on a C57BL/6 background. Mice (n=13-
15 per group) were injected with either RAL (0.5 mg/kg; 5x/week), zoledronate (ZOL;
80 µg/kg; at 8 weeks and 12 weeks of age), or the combination. Untreated controls
were also included. These dosages were chosen based on previous research showing
efficacy in vivo. [34–37] Treatments began at 8 weeks of age and extended for 8 weeks.
At 16 weeks of age, the mice were euthanized, at which time right femora and tibiae
were harvested, stripped of soft tissue, and frozen in saline-soaked gauze at -20◦C.
2.2 Microcomputed Tomography (µCT) and Architectural Analysis
To determine the effects of treatment on bone architecture, right femora and
right tibiae were scanned at 10-micron resolution (Skyscan 1172, Bruker). Scans
were performed using a 0.7-degree angle increment, two frames averaged, through
a 0.5mm Al filter (V = 60kV, I = 167µA). Images were reconstructed (nRecon)
and calibrated to hydroxyapatite-mimicking phantoms (0.25 and 0.75 g/cm3 Ca-HA).
1-mm trabecular regions were selected and quantified using CT Analyzer (CTAn).
The region for the femora was selected at the distal metaphysis and extended 1mm
proximally from the most proximal portion of the growth plate. The trabecular region
for the tibiae was selected at the proximal metaphysis and extended 1-mm distally
7from the most distal portion of the growth plate. A 1-mm cortical region was selected
at approximately 50% length of the femur, then analyzed with a custom MATLAB
program to obtain architectural properties. [38]
2.3 Three-point Bending Mechanical Testing to Failure
Each femora was tested to failure in three-point bending (support span at 8mm)
with the anterior surface in tension. The bones were loaded at a displacement control
rate of 0.25 mm/sec while the sample remain hydrated with PBS. Cross sectional cor-
tical properties at the femoral mid-point were obtained with µCT images as described
above. These properties were used to map load-displacement data into stress-strain
data using standard engineering equations as previously reported. [39]
2.4 Fracture Toughness Testing
Fracture toughness of the right tibiae was measured using a linear elastic fracture
mechanics approach. [40,41] A notch was made on the anteromedial side of the tibia,
at approximately 50% length, using a scalpel blade lubricated with a 1 µm diamond
suspension. The tibiae were notched into the medullary cavity to a depth not ex-
ceeding the bones midpoint. They were then tested to failure in 3 point bending at a
displacement control rate of 0.001 mm/sec with the notched surface in tension. The
load point was positioned directly above the notch site.
After mechanical testing, the bones were cleansed of marrow and dehydrated using
an ethanol gradient (70-100%) and a vacuum desiccator. Following sputter-coating
with gold, the cross-sectional fracture surface was imaged with scanning electron
microscopy (SEM). The angles of stable and unstable crack growth were obtained
from the images and, along with geometric properties from µCT data, a custom
MATLAB program calculated stress intensity factors for crack initiation, maximum
load, and fracture instability.
82.5 Statistical Analysis
Within each genotype, a One-Way ANOVA with post-hoc Dunnetts test was used
to statistically analyze the effect of each treatment versus control. Analysis was
performed using GraphPad Prism (v.8) with a significance level at 0.05.
9CHAPTER 3. RESULTS
3.1 Trabecular Architecture and Mineralization
Bone volume fraction in the femoral distal metaphysis was significantly higher
compared to control in both genotypes with ZOL monotherapy and combination
treatment, but not with RAL monotherapy (Fig. 3.1). In both genotypes, trabecular
number was significantly increased with ZOL alone and with combinatorial therapy,
but not with RAL alone. Although trabecular thickness trended upward with RAL
in both WT (+7.1%) and OIM+/- (+5.8%), it only reached significance with com-
bination treatment which substantially increased in both genotypes (WT:+24.7%;
OIM+/-:+20.9%). As a result, trabecular spacing was decreased in both genotypes
with ZOL alone and combination therapy. Tissue mineral density (TMD) was signifi-
cantly elevated with the combination treatment in both genotypes. RAL monotherapy
significantly increased TMD in the WT mice and trended upward in OIM+/-. ZOL
had no effect on TMD in either genotype. Identical results were demonstrated at the
proximal tibial metaphysis (data not shown).
3.2 Cortical Geometry at the Femoral Mid-Diaphysis
There were no significant changes with either monotherapy or combinatorial treat-
ment in any cortical properties at the femoral mid-diaphysis (Table 3.1, Table 3.2).
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(a) Bone Volume Fraction (BV/TV) (b) Trabecular Number (Tb.N)
(c) Trabecular Thickness (Tb.Th) (d) Trabecular Separation (Tb.Sp)
(e) Tissue Mineral Density (TMD)
Fig. 3.1: Treatment Effects on Trabecular Properties.
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Table 3.1: WT Cortical Geometry
Property Control RAL ZOL RAL+ZOL
Total CSA
(mm2)
2.031±0.174 2.068±0.193 2.011±0.216 2.053±0.190
Marrow Area
(mm2)
1.051±0.100 1.047±0.116 1.027±0.104 1.028±0.102
Cortical Area
(mm2)
0.980±0.113 1.020±0.084 0.984±0.129 1.024±0.107
Cortical Th.
(mm)
0.227±0.021 0.235±0.010 0.230±0.021 0.238±0.017
Periosteal
Pm. (mm)
5.868±0.231 5.921±0.239 5.852±0.271 5.898±0.240
Endocortical
Pm. (mm)
4.581±0.224 4.533±0.242 4.530±0.282 4.500±0.218
Imax (mm
4) 0.346±0.064 0.366±0.061 0.347±0.074 0.366±0.067
Imin (mm
4) 0.168±0.031 0.177±0.035 0.165±0.041 0.174±0.035
TMD (g/cm3) 1.272±0.021 1.267±0.048 1.277±0.024 1.280±0.021
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Table 3.2: OIM+/- Cortical Geometry
Property Control RAL ZOL RAL+ZOL
Total
CSA(mm2)
1.897±0.267 1.837±0.167 1.965±0.310 1.834±0.194
Marrow Area
(mm2)
0.974±0.128 0.902±0.096 0.979±0.157 0.906±0.116
Cortical Area
(mm2)
0.923±0.179 0.935±0.092 0.987±0.176 0.929±0.091
Cortical Th.
(mm)
0.225±0.040 0.231±0.017 0.238±0.036 0.229±0.013
Periosteal
Pm. (mm)
5.684±0.357 5.630±0.250 5.789±0.395 5.611±0.254
Endocortical
Pm. (mm)
4.414±0.301 4.286±0.265 4.513±0.543 4.247±0.256
Imax (mm
4) 0.300±0.084 0.301±0.058 0.329±0.081 0.292±0.058
Imin (mm
4) 0.151±0.045 0.139±0.025 0.166±0.073 0.142±0.032
TMD (g/cm3) 1.309±0.032 1.314±0.031 1.307±0.035 1.314±0.037
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3.3 Femoral Mechanical Strength and Stiffness
The majority of significant effects noted in femoral mechanical properties versus
control occurred in strength parameters (Fig. 3.2, Table 3.3-3.6). At the structural
level, RAL monotherapy and combination treatment resulted in higher yield force in
both genotypes. ZOL monotherapy also significantly increased the property but only
in WT. Ultimate force was significantly elevated versus control by the combination
treatment in both genotypes. At the tissue level, ultimate stress was significantly
higher with combination treatment compared to control in both genotypes. RAL
alone increased ultimate stress in OIM+/- but not in WT. Yield stress significantly
increased with all treatments in OIM+/-. Although the property trended up in WT,
it did not reach significance (ANOVA p=0.10). Increased yield stress led to increased
resilience in OIM+/- with RAL and combination treatment versus control, but not
with ZOL alone.
A few non-strength parameters were also impacted by treatment. Stiffness was
significantly higher with all treatments in OIM +/-, but in WT, only increased with
RAL monotherapy and combination therapy. The combination treatment in WT also
resulted in greater modulus and decreased total strain compared to control.
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(a) Schematic Force-Displacement Curves for WT (A) and OIM +/- (B)
(b) Schematic Stress-Strain Curves for WT (A) and OIM +/- (B)
Fig. 3.2: Treatment Effects on Mechanical Properties.
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Table 3.3: WT Structural Mechanical Properties
Property Control RAL ZOL RAL+ZOL
Yield Force
(N)
12.7±1.3 14.7±1.6* 14.3±2.0* 14.7±1.8*
Ultimate
Force (N)
17.6±2.4 19.8±2.1 18.8±3.4 20.8±3.1*
Displ. to
Yield (µm)
148.4±30.6 138.5±21.9 148.8±17.3 130.6±12.8
Postyield
Displ. (µm)
899.9±417.0 590.8±291.5 638.9±395.6 539.6±196.0*
Total Displ.
(µm)
1048.3±421.5 729.3±292.5* 787.8±407.1 670.2±197.6*
Stiffness
(N/mm)
97.7±18.9 120.1±19.7* 107.9±21.7 125.8±14.5*
Work to Yield
(mJ)
1.02±0.23 1.11±0.23 1.15±0.17 1.05±0.20
Postyield
Work (mJ)
11.20±4.29 9.46±4.33 9.36±4.27 9.62±3.52
Total Work
(mJ)
12.22±4.22 10.57±4.37 10.51±4.37 10.67±3.60
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Table 3.4: OIM+/- Structural Mechanical Properties
Property Control RAL ZOL RAL+ZOL
Yield Force
(N)
11.9±2.0 14.1±1.7* 13.7±1.8 14.3±2.2*
Ultimate
Force (N)
14.8±1.6 16.2±1.6 16.4±2.5 17.4±2.2*
Displ. to
Yield (µm)
142.9±18.9 147.0±12.8 142.1±20.4 142.8±16.1
Postyield
Displ. (µm)
343.8±177.3 215.7±120.3 261.7±156.5 238.2±100.6
Total Displ.
(µm)
486.6±181.4 362.7±121.6 403.9±152.0 381.0±104.3
Stiffness
(N/mm)
92.4±9.9 107.0±14.5* 107.9±17.0* 111.5±16.0*
Work to Yield
(mJ)
0.93±0.25 1.13±0.19 1.06±0.25 1.12±0.24
Postyield
Work (mJ)
4.61±2.49 3.10±1.51 3.97±2.48 3.79±1.69
Total Work
(mJ)
5.54±2.55 4.23±1.47 5.03±2.50 4.90±1.82
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Table 3.5: WT Tissue-Level Mechanical Properties
Property Control RAL ZOL RAL+ZOL
Yield Stress
(MPa)
143.0±30.8 161.0±24.3 167.2±29.5 167.3±33.7
Ultimate
Stress (MPa)
194.3±26.7 215.5±20.3 217.7±35.5 236.6±49.3*
Strain to
Yield (µ)
22914±3944 21046±3527 22730±2826 20105±1851
Total Strain
(µ)
162283±63490 113172±52024 119577±57193 104288±33407*
Modulus
(GPa)
6.92±1.19 8.65±1.60 8.33±2.54 9.39±2.34*
Resilience
(MPa)
1.80±0.62 1.85±0.49 2.03±0.35 1.83±0.39
Toughness
(MPa)
21.30±7.60 17.34±6.27 18.53±7.63 18.28±5.71
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Table 3.6: OIM+/- Tissue-Level Mechanical Properties
Property Control RAL ZOL RAL+ZOL
Yield Stress
(MPa)
143.3±24.4 187.0±42.5* 172.5±35.6* 183.2±17.4*
Ultimate
Stress (MPa)
179.3±30.5 213.3±37.1* 205.4±34.0 224.7±23.3*
Strain to
Yield (µ)
21270±4099 21929±2287 21418±3764 21303±3255
Total Strain
(µ)
72862±30109 54960±20533 60239±21398 57002±16760
Modulus
(GPa)
7.74±2.19 9.69±3.20 9.09±2.11 9.76±1.82
Resilience
(MPa)
1.64±0.38 2.20±0.43* 2.03±0.69 2.13±0.40*
Toughness
(MPa)
9.66±4.03 8.12±2.68 9.15±3.8 9.23±2.78
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3.4 The Effect of Combination Treatment on Fracture Toughness
Combination treatment in OIM+/- led to significantly higher stress intensity fac-
tors at crack initiation and maximum load (Fig. 3.3). Neither monotherapy sig-
nificantly changed fracture toughness in OIM+/-. Treatment in WT produced no
significant effects in the stress intensity factors.
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(a) Fracture Toughness of OIM+/- at Crack Initiation, Maximum Load, and Failure
(b) Fracture Toughness of WT at Crack Initiation, Maximum Load, and Failure
Fig. 3.3: Effects of Treatment on Fracture Toughness.
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CHAPTER 4. CONCLUSION
4.1 Discussion
Current therapeutics used to combat bone fragility are insufficient on their own to
optimize bone quality and improve fracture resistance in diseased states. Targeting
different mechanisms with a combination treatment could be a potentially powerful
technique to enhance bone on both a macroscopic and tissue level. The goal of this
study was to investigate how the mass-based effects of bisphosphonates, combined
with the tissue-level improvements seen with raloxifene, would improve bone quantity,
quality, and fracture resistance. The results demonstrate that ZOL and RAL could
be used together to enhance trabecular architecture, cortical mechanical properties,
and tissue fracture toughness more than either treatment alone, especially in diseased
bone.
For trabecular architecture, the combination treatment appeared to be following
the dominant effects of ZOL with an increase in bone volume fraction and trabecular
number and a decrease in trabecular spacing. ZOL did not impact trabecular thick-
ness. These trabecular findings are consistent with previous research investigating
BPs use in adolescent OI mice. [42–45] The results are unsurprising as at this rela-
tively young age, trabecular bone is often lost with longitudinal growth coupled with
resorptive modeling. BP use effectively inhibited this modeling and, thus, maintained
bone volume.
Although RAL exhibited an overall minimal effect on trabecular structure, there
was a trend toward increased trabecular thickness which contributed to a substantial
elevation of thickness when combined with ZOL in both genotypes. RAL alone also led
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to increased tissue mineral density. TMD markedly amplified with the combination
therapy, potentially since more bone was available to mineralize due to the mass-
based effects of ZOL. Male mice were used in this study to limit the cellular metabolic
actions of RAL through ER signaling. This suggests that RAL in males may produce
quality-based tissue changes through mostly cell-independent mechanism. Similar
changes have previously been note with RAL use. [37,43]
There were no significant effects on cortical geometry with any treatment in either
genotype. In cortical bone, metabolic activity is lower, and it was expected that
ZOL would have little effect on mass. [42–45] RAL is also expected to have limited
geometric effect in cortical locations, however, previous research has demonstrated
significant increases in cortical thickness that were not reproduced in this study.
[37,43] This discrepancy could be due to differences in animal age, background strain,
or vendor. Regardless, the lack of geometric changes suggests that any differences in
mechanic properties are most likely driven by changes at the intrinsic tissue level.
The significant effects of treatment versus control on mechanical behavior were
mostly related to strength parameters. ZOL had a modest impact on its own, sig-
nificantly increasing yield force in WT and yield stress in OIM+/-. The effects of
RAL alone were more compelling, and drove the changes also seen with combination
treatment. Yield stress increased in OIM+/- with RAL and combination treatment
which led to a significant increase in resilience, indicting the bones were able to absorb
more energy before yielding. Unlike previous work with RAL, post yield mechani-
cal behavior was not affected. [34, 37, 43] Here, control groups from both genotypes
showed far more total deformation than expected based on previous work with this
age and sex of mouse, and the majority of this deformation occurred post yield. It is
not clear why this was the case, but it removed the possibility of detecting post yield
effects of treatment if they exist. The tissues also stiffened with all the treatments.
Bone tissue is known to stiffen with BPs, however, a significant increase in stiffness
is somewhat unexpected with RAL. [34, 37, 43] As noted above, these discrepancies
could be based on differences in the mice used in this study. Regardless, the net result
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is that treatment improved stiffness and strength parameters in bone, and the effect
was most pronounced with combination therapy.
Perhaps the most important finding here is that the combination treatment im-
proved stress intensity factors at crack initiation and maximum load in the diseased
mice. This type of test reflects true material-level properties in bone and indicates
improved fracture resistance in diseased bone with this combined treatment. Treat-
ment did not impact WT mice, likely because it is difficult to improve bone that is
already of good quality. Previous work with RAL showed an increase in maximum
load toughness with treatment, but RAL alone did not produce the same effects here.
This could be due to differences in sample sizes or discrepancies with the notching
technique used. Similar to the results of this study, fracture toughness has not been
shown to improve with BP treatment. In skeletally mature rabbits, ZOL injections did
not improve fracture toughness on ulnar sections. [46] In humans, long term BP use
has even been shown to compromise fracture toughness on femoral corticocancellous
biopsies. [47]
BPs are the only FDA approved drug for pharmaceutical treatment of Osteo-
genesis Imperfecta. A recent review paper compiled over 15 years of clinical trials
investigating BPs use in patients with OI. It was determined that while both oral and
IV BPs substantially improved BMD, it was unclear whether BPs consistently im-
prove fracture resistance and decrease fracture risk. Continuous use of BPs in children
and teenagers with OI has revealed some negative impacts on bone health, including
microdamage accumulation, delayed healing, and increased mineralization. [48–50]
These findings confirm the need for treatments that focus on improving bone quality,
in addition to quantity, to improve skeletal fragility and prevent fracture. The fact
that we have shown a positive combined treatment effect on measures of fracture
resistance in diseased bone, effectively returning these properties to near WT control
levels, is promising and future work will focus on treatment strategies to optimize
this effect.
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4.2 Limitations and Future Work
There are some limitations to our study. Male mice were chosen in attempt to
reduce the metabolic effects of RAL and utilize its cell-independent mechanism. This
was intentional, but could limit the findings. Future work should be conducted to
assess treatment effects on both sexes. With fracture toughness testing, sample sizes
were not consistent across groups. Numerous bones were accidentally broken during
the notching process. It was also difficult to determine the transition lines of crack
propagation for several samples. Homozygous (OIM-/-) mice were originally included
in this study. However, the severity of the phenotype caused numerous spontaneous
fractures in the untreated mice, and only 2 control samples were usable for analysis.
Lastly, the age of the mice used here could be controversial. The mice received
treatment from 8 weeks to 16 weeks. The age group was chosen to mirror the rapid
growth during human adolescence, and potentially when treatment might be started
in humans with OI. This age could have led to the high deformation in the control
groups due to rapid modeling and slow mineralization. It is also problematic because
it does not coincide with an age that humans receive RAL, as RAL is typically
only administered in older adults. Future studies will also investigate the effects of
combined treatment in older animals, following skeletal maturity.
The use of RAL has some limitations in itself. Although RAL possesses beneficial
intrinsic effects, it may not necessarily be the most ideal drug to pursue for combina-
torial therapy. RAL suppresses bone loss as a selective estrogen receptor modulator
(SERM), but this estrogen therapy produces adverse effects such as hot flashes and
increased thrombosis risk, making it a problematic treatment. The estrogen receptor
binding also prevents usage in some at-risk patient populations including children,
specifically those with OI. [51, 52] Other drugs could be considered for a combina-
tion treatment. Recent work has shown positive outcomes in OI patients and OI
mice treated with sclerostin antibody and denosumab. [45,53,54] These compounds,
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amongst others, should be investigated to determine an ideal combination and dosing
schedule.
In conclusion, the current study shows beneficial effects of combination therapy
to enhance quality of diseased bone in a way that neither treatment could accomplish
alone. Utilizing the mass-based effects of ZOL with the tissue material changes of
RAL, the combination therapy improved fracture toughness in addition to increases in
trabecular architecture and cortical mechanics, especially in diseased animals. Com-
binatorial treatments should be considered for future therapies to optimize patient
care and bone health.
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